Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
255
Frequently Asked Questions
What is Market Cap of Verve Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Verve Therapeutics Inc market cap is $409.24M.
What is the 52-week high for Verve Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Verve Therapeutics Inc 52 week high is $21.42 as of June 08, 2024.
What is the 52-week low for Verve Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Verve Therapeutics Inc 52 week low is $4.90 as of June 08, 2024.
What is Verve Therapeutics Inc stock price today?
Verve Therapeutics Inc stock price today is $5.21.
What was Verve Therapeutics Inc stock price yesterday?
Verve Therapeutics Inc stock price yesterday was $5.28.
What is the PE ratio of Verve Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Verve Therapeutics Inc’s P/E ratio is -1.81.
What is the Price-to-Book ratio of Verve Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Verve Therapeutics Inc P/B ratio is 0.7490.
What is Verve Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Verve Therapeutics Inc's EBITDA is -2.69.
What is the 50-day moving average of Verve Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Verve Therapeutics Inc 50-day moving average is $6.72.
How many employess does Verve Therapeutics Inc has?